Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Recurrence × axicabtagene ciloleucel × Clear all

Status

Approved for marketing 1

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 6 Lymphoma, Follicular 3 Lymphoma, B-Cell 2 Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma 1 Hematologic Neoplasms 1

Interventions

Dexamethasone 53 Lenalidomide 29 Cyclophosphamide 29 pomalidomide 27 Rituximab 27 Bortezomib 24 venetoclax 23 fludarabine 21 Paclitaxel 19 carfilzomib 18 Gemcitabine 18 Cisplatin 15 Carboplatin 15 pembrolizumab 14 daratumumab 14 Docetaxel 12 Calcium Dobesilate 12 Azacitidine 12 obinutuzumab 11 ibrutinib 11 Cytarabine 11 Nivolumab 10 Bevacizumab 10 tisagenlecleucel 9 Injections 9 durvalumab 8 cemiplimab 8 blinatumomab 8 Doxorubicin 8 Cetuximab 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03153462 2023-11-08

ZUMA-9

Gilead Sciences

Approved for marketing

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡